Skip to main content
. 2021 Jan 13;24(2):102058. doi: 10.1016/j.isci.2021.102058

Figure 2.

Figure 2

GSK-3β-HK mice model used in this study

(A) Representative images of western blots using EC lysates from WT and GSK-3β-HK mice probed for kinases known to phosphorylate tau.

(B) Quantification of western blots. Results showed a significant overall reduction of 45% of GSK-3β and 40% of pGSK-3β (active and inhibited forms, -Tyr216 and -Ser9, respectively) in GSK-3β-HK compared with WT mice. No differences were found in GSK-3α, pGSK-3α-Tyr279 (active GSK-3α), FYN, and CDK5 between WT and GSK-3β-HK mice. Data are presented as mean ± SEM, N = 14 mice: 7WT, 7HK. Two-tailed Student's t test, ∗∗p < 0.01, ∗∗∗p < 0.001.

(C) Representative images of western blots probed for hTau and Total Tau (mouse + human tau (ms + h)) in AAV-injected mice.

(D) Quantification of western blots showed no difference in Total Tau (ms + h) and hTau in the EC of WT and GSK-3β-HK mice (AAV-injected). GAPDH was used as loading control for all proteins. pGSK-3 and hTau were also normalized by total GSK-3β and Total Tau, respectively (as indicated in graphs). Data are presented as mean ± SEM, N = 14 mice: 7WT, 7HK. Two-tailed Student's t test, p > 0.05.